Financial health
- Operating income covered interest expense -1265.4× in the latest year, down from -246.8× 5 years ago.
14 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | — | -$22M | — | — | -214.9% | -154.9% | — | — | $9M |
| 2025 | — | -$18M | — | — | -92.3% | -81.4% | — | — | $18M |
| 2024 | — | -$32M | — | — | -207.1% | -127.4% | — | — | $24M |
| 2023 | — | -$50M | — | — | -327.6% | -143.2% | — | — | $19M |
| 2022 | — | -$26M | — | — | -710.6% | -129.7% | — | — | $19M |
| 2021 | — | -$130M | — | — | -2579.0% | -2154.1% | — | — | — |
| 2020 | — | -$17M | — | — | 77.6% | -800.3% | — | $62500 | — |
| 2018 | — | -$2M | — | — | -2189.0% | -111.9% | — | — | — |
| 2017 | — | -$1M | — | — | -115.0% | -56.3% | — | — | — |
| 2016 | — | -$431923 | — | — | -22.5% | -15.9% | — | — | — |
| 2015 | — | -$233008 | — | — | 430.5% | -86.5% | — | — | — |
| 2014 | — | -$321896 | — | — | -187.8% | -96.7% | — | — | — |
| 2014 | — | -$166170 | — | — | -46.5% | -46.2% | — | — | — |
| 2013 | — | -$17510 | — | — | -3.6% | -3.5% | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$5M | — | — | -33.8% | -30.1% | — | — | $13M |
| Dec '25 | — | -$6M | — | — | -31.5% | -27.0% | — | — | $21M |
| Sep '25 | — | -$5M | — | — | -20.4% | -19.0% | — | — | $25M |
| Mar '25 | — | -$3M | — | — | -12.8% | -11.3% | — | — | $23M |
| Dec '24 | — | -$7M | — | — | -29.7% | -27.7% | — | — | $24M |
| Sep '24 | — | -$4M | — | — | -29.5% | -19.6% | — | — | $20M |
| Mar '24 | — | -$8M | — | — | -42.6% | -25.4% | — | — | $30M |
| Dec '23 | — | -$8M | — | — | -112.2% | -39.1% | — | — | $20M |
| Sep '23 | — | -$11M | — | — | -141.9% | -45.1% | — | — | $21M |
| Mar '23 | — | -$15M | — | — | -69.3% | -33.3% | — | — | $31M |
| Dec '22 | — | -$16M | — | — | -60.2% | -33.2% | — | — | — |
| Sep '22 | — | -$10M | — | — | -174.7% | -45.6% | — | — | — |
| Jun '22 | — | -$8M | — | — | -220.3% | -40.2% | — | — | $19M |
| Mar '22 | — | -$7M | — | — | -70.7% | -26.9% | — | — | — |
| Dec '21 | — | -$5M | — | — | -33.7% | -17.0% | — | — | — |
| Sep '21 | — | -$6M | — | — | -27.4% | -25.2% | — | — | — |
| Jun '21 | — | -$132M | — | — | -2604.4% | -2175.3% | — | — | — |
| Mar '21 | — | -$3M | — | — | -26.2% | -23.2% | — | $62500 | — |
| Dec '20 | — | -$3M | — | — | -23.4% | -22.7% | — | $62500 | — |
| Sep '20 | — | $7M | — | — | 50.2% | 49.3% | — | $62500 | — |
See the revenue and net-income charts above for BIOVIE INC.'s multi-year trend.
As of FY2026, BIOVIE INC. reported — of total debt against $9M of cash; operating income covered interest expense -1265.4×.
In FY2026, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.